Schaeffer's Top Stock Picks for '25

Analyst Update: BioMarin Pharmaceutical Inc., Anthem Inc, and Tesla Motors Inc

Analysts revised their ratings and price targets on BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), Anthem Inc (NYSE:ANTM), and Tesla Motors Inc (NASDAQ:TSLA)

Jul 28, 2016 at 3:39 PM
facebook X logo linkedin


Analysts are weighing in on gene therapy specialist BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), health insurer Anthem Inc (NYSE:ANTM), and auto stock Tesla Motors Inc (NASDAQ:TSLA)Here's a quick roundup of today's brokerage notes on BMRN, ANTM, and TSLA. 

  • Analysts are quickly raising their expectations on ​BMRN​, after the company yesterday provided promising data on its gene therapy for hemophilia. Credit Suisse, Baird, William Blair, and BMO all raised their price targets on the stock, with the last firm providing the loftiest target at $118. With BioMarin Pharmaceutical Inc. trading up 0.3% at $98.42, this represents upside of 20% -- an ambitious prediction, considering the stock's 32% decline over the past 12 months. This bullish attention is far from unusual, however, as 14 of 15 brokerage firms consider BMRN a "buy" or "strong buy." Looking ahead, the company is scheduled to report earnings a week from today. 
  • Elsewhere, a series of events has ANTM 0.7% lower at $132.96. First off, Moody's late yesterday confirmed its rating on the company, suggesting it sees little chance of the insurance company merging with CIGNA Corporation (NYSE:CI), following a lawsuit from the Department of Justice (DOJ). A round of bearish notes has hit Anthem Inc since Wednesday's close, too. At least six brokerage firms reduced their price targets, including a cut to $151 from $158 at Barclays. Put traders have also been pounding the stock, which is down almost 5% in 2016. ANTM's 10-day put/call volume ratio at the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) comes in at 3.03 -- higher than roughly four-fifths of similar readings from the past year. 
  • TSLA was last seen 0.7% higher at $230.07, following upbeat comments at Fidelity. Gavin Baker, who manages the firm's over-the-counter (OTC) portfolio that invests in Tesla, said, "We foresee fruitful synergies between Tesla and any company in search of superior battery technology, and we modestly increased our position this quarter." Still, Tesla Motors Inc shares remain in the red on a year-to-date basis, and are battling resistance at their 320-day moving average. Speculators remain upbeat, though, as call buying has outpaced put buying during the past two weeks at the ISE, CBOE, and PHLX. Looking ahead, TSLA is slated to reported earnings next Wednesday night.
Don't miss the market's next move! Sign up now for Schaeffer's Midday Market Check
 
 

You have the chance to join one of Bernie's most exclusive programs, complete access at HUGE savings!

As we prepare for a new administration to take the reins in Washington, the near-term market landscape is rife with uncertainty.

The Federal Reserve has already hinted at the turbulence ahead, lowering its interest rate outlook for 2025.

Meanwhile, breakthroughs in artificial intelligence (AI), quantum computing, and other transformative sectors have unlocked incredible profit potential.

But these opportunities are fleeting, and timing is everything. That's where Quick-Hit Trader comes in.

Quick-Hit Trader is designed for precision and speed, getting you in and out of the market in a flash. While other investors scramble to navigate volatile conditions, you'll have access to expertly curated trades that leverage these rapid shifts to deliver explosive profits in short order.

This is your chance to capitalize on the fast-moving market like never before. Are you ready to make your move?